...
首页> 外文期刊>Therapeutic Drug Monitoring >Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory.
【24h】

Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory.

机译:伏立康唑治疗药物监测的临床医生订购实践:转诊实验室的经验。

获取原文
获取原文并翻译 | 示例
           

摘要

Monitoring of serum voriconazole concentrations has been proposed to optimize therapeutic effect and minimize toxicity. However, little is known about the clinical use of voriconazole therapeutic drug monitoring (TDM) by treating physicians. Four hundred seventy-eight episodes corresponding with 161 adult patients (mean three TDM episodes per patient; range 1-31, at a mean interval 43.6 days [range 1-266] between repetitions) performed at a state reference laboratory in Australia during a 30-month period were reviewed. Information about voriconazole dose was provided on only nine (1.9%) request forms. Timing of voriconazole TDM in relation to the previous dose was stated in 189 (39%) episodes and corresponded with peak measurements in 16; interval measurements (taken on average 3.3 [range 3-10.5] hours from the preceding dose) in 15; and trough measurements in 158 episodes. Of the 158 trough concentration measurements, only 66 (42%) were between 1 and 5.5 mg/L, the suggested therapeutic range. Similarly, only 33% (98 of 298) of all the random TDM episodes achieved voriconazole concentrations greater than 2.05 mg/L, previously associated with favorable outcomes. Compared with trough TDM, random episodes were significantly more likely to result in undetectable (less than 0.1 mg/L) concentrations (45 of 298 [15.1%] versus 12 of 158 [7.6%]; P = 0.021, odds ratio 2.16, 95% confidence interval: 1.11-4.22). Among patients with multiple TDM episodes, there was no correlation between the initial and final trough or between the initial and final random concentrations. Only 44% (eight of 18) of patients with multiple trough TDM had final concentration within 1 to 5.5 mg/L; and only 26% (15 of 58) of patients with multiple random TDM had final concentration greater than 2.05 mg/L. Adoption of consistent and clear guidelines on voriconazole TDM use and education of physicians ordering the test is required because the majority of testing performed was inappropriate and prone to suboptimal interpretation.
机译:已经提出了监测伏立康唑浓度的方法以优化治疗效果并使毒性最小化。然而,关于伏立康唑治疗药物监测(TDM)在临床上的使用,临床医生知之甚少。在30天内于澳大利亚的州参比实验室进行了487次发作,分别对应161名成年患者(平均每名患者3次TDM发作;范围1-31,平均间隔43.6天[重复之间1-266]次)个月的时间进行了审查。关于伏立康唑剂量的信息仅在九份(1.9%)申请表中提供。伏立康唑TDM相对于先前剂量的时间安排在189次(39%)发作中说明,与16次中的峰值测量结果相对应;间隔测量(从前一剂开始平均平均3.3 [范围3-10.5]小时)在15中进行;和158集的低谷测量。在158个谷浓度测量中,只有66个(42%)的浓度介于1至5.5 mg / L之间,这是建议的治疗范围。同样,在所有随机TDM发作中,只有33%(298个中的98个)达到伏立康唑浓度大于2.05 mg / L的水平,以前与良好的预后相关。与低谷TDM相比,随机发作更可能导致无法检测(低于0.1 mg / L)的浓度(298的45 [15.1%]比158的12 [7.6%]; P = 0.021,优势比2.16、95 %置信区间:1.11-4.22)。在患有多个TDM发作的患者中,初始和最终波谷之间或初始和最终随机浓度之间没有相关性。多谷TDM患者中只有44%(18名患者中的8名)终浓度在1至5.5 mg / L之内。仅有26%(58名患者中的15名)患有多种随机TDM的患者终浓度超过2.05 mg / L。由于伏立康唑TDM使用的一致性和明确的指导方针以及对医生进行订购测试的教育是必需的,因为所进行的大多数测试均不合适并且容易导致次优的解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号